325 related articles for article (PubMed ID: 30985507)
21. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
22. Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.
Harboe ZB; Valentiner-Branth P; Ingels H; Rasmussen JN; Andersen PH; Bjerre CC; Goldblatt D; Ashton L; Haston M; Konradsen HB; Lambertsen L;
PLoS One; 2013; 8(1):e51460. PubMed ID: 23365635
[TBL] [Abstract][Full Text] [Related]
23. Have changing pneumococcal vaccination programmes impacted disease in Ontario?
Lim GH; Wormsbecker AE; McGeer A; Pillai DR; Gubbay JB; Rudnick W; Low DE; Green K; Crowcroft NS; Deeks SL
Vaccine; 2013 May; 31(24):2680-5. PubMed ID: 23597716
[TBL] [Abstract][Full Text] [Related]
24. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
[TBL] [Abstract][Full Text] [Related]
25. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
26. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Miron D; Aviner S; Dagan R;
Vaccine; 2016 Aug; 34(38):4543-4550. PubMed ID: 27475471
[TBL] [Abstract][Full Text] [Related]
27. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.
van der Linden M; Weiß S; Falkenhorst G; Siedler A; Imöhl M; von Kries R
Vaccine; 2012 Aug; 30(40):5880-5. PubMed ID: 22771186
[TBL] [Abstract][Full Text] [Related]
28. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
[TBL] [Abstract][Full Text] [Related]
29. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Lexau C; Bennett NM; Petit S; Zansky SM; Harrison LH; Reingold A; Miller L; Scherzinger K; Thomas A; Farley MM; Zell ER; Taylor TH; Pondo T; Rodgers L; McGee L; Beall B; Jorgensen JH; Whitney CG
Lancet Infect Dis; 2015 Mar; 15(3):301-9. PubMed ID: 25656600
[TBL] [Abstract][Full Text] [Related]
30. Long-term trends in invasive pneumococcal disease in Manitoba, Canada.
Mahmud SM; Sinnock H; Mostaço-Guidolin LC; Pabla G; Wierzbowski AK; Bozat-Emre S
Hum Vaccin Immunother; 2017 Aug; 13(8):1884-1891. PubMed ID: 28494193
[TBL] [Abstract][Full Text] [Related]
31. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.
Gladstone RA; Jefferies JM; Faust SN; Clarke SC
Expert Rev Vaccines; 2012 Aug; 11(8):889-902. PubMed ID: 23002969
[TBL] [Abstract][Full Text] [Related]
32. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S
Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303
[TBL] [Abstract][Full Text] [Related]
33. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J
Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.
Deceuninck G; De Serres G; Boulianne N; Lefebvre B; De Wals P
Vaccine; 2015 May; 33(23):2684-9. PubMed ID: 25887086
[TBL] [Abstract][Full Text] [Related]
35. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of Severe and Non-severe Invasive Pneumococcal Disease in Young Children in Israel Following PCV7/PCV13 Introduction.
Glikman D; Dagan R; Barkai G; Averbuch D; Guri A; Givon-Lavi N; Ben-Shimol S;
Pediatr Infect Dis J; 2018 Oct; 37(10):1048-1053. PubMed ID: 29750768
[TBL] [Abstract][Full Text] [Related]
37. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
Ingels HA
Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
[TBL] [Abstract][Full Text] [Related]
38. Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.
García Gabarrot G; López Vega M; Pérez Giffoni G; Hernández S; Cardinal P; Félix V; Gabastou JM; Camou T;
PLoS One; 2014; 9(11):e112337. PubMed ID: 25375647
[TBL] [Abstract][Full Text] [Related]
39. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.
Picazo J; Ruiz-Contreras J; Casado-Flores J; Giangaspro E; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C;
Pediatr Infect Dis J; 2013 Jun; 32(6):656-61. PubMed ID: 23249906
[TBL] [Abstract][Full Text] [Related]
40. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
